Full Title
A Phase Ib trial with Dose Expansion of Epcoritamab in Combination with Ibrutinib in Refractory/Recurrent CNS lymphoma (EIFEL-Trial)Purpose
Researchers want to see if the combination of epcoritamab and ibrutinib is a safe treatment for people with central nervous system lymphoma (CNSL) that keeps growing or came back after treatment.
Epcoritamab is a type of drug called a bispecific antibody. It binds to one protein on the surface of cancer cells and another protein on immune cells called T cells. When epcoritamab attaches to these proteins at the same time, it activates T cells to kill cancer cells. It is given as a subcutaneous (under the skin) injection.
Ibrutinib targets proteins called kinases found in cancer cells. Cancer cells need these proteins to survive and grow. By blocking these proteins, ibrutinib may kill cancer cells or stop their growth. It is taken orally (by mouth).
Giving epcoritamab and ibrutinib together may work better than either drug given alone.
Who Can Join
To join this study, there are a few conditions. You must:
- Have primary or secondary CNSL that keeps growing or came back after treatment.
- Have completed prior anti-cancer medications at least 4 weeks prior and radiation therapy at least 3 weeks before getting the study treatment.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Christian Grommes’ office at 212-610-0344.